Print
Email
Print Edition StoriesFriday, July 11, 2008
PerkinElmer turns ViaCord into stem cell R&D arm
By Mass High Tech Staff
PerkinElmer Inc., a company focused on the health sciences and photonics markets, says it has begun efforts to further its research and development of stem cell-related products.
Waltham-based PerkinElmer (NYSE: PKI) has formed the ViaCord Research Institute, which will focus on using umbilical cord blood-derived stem cells for cord blood technologies, emerging stem cell therapies, genetic screening, product development and related transplants. PerkinElmer acquired its cord blood business through its $300 million buyout of Cambridge-based ViaCell Inc. in October 2007.
The institute will be led by Morey Kraus, chief technology officer of the ViaCord business, and advised by a board of researchers and ViaCord scientists.
PerkinElmer, which employs 9,100 workers worldwide, reported 2007 net income of $131.7 million on revenue of $1.8 billion.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
